Top Oil Service Companies To Invest In 2015

The U.S. energy boom is exciting, it's notable, and it could change the world. At the same time, there are still plenty of places around the world that will need to import oil. The major supplier of that demand has been, and will continue to be, the Middle East. The nations that constitute the Middle East produce about 30% of the world's oil, and some countries in the region are looking to step up their game.

The biggest plans to increase production in the Middle East right now focus on Iraq. Ministers in the country hope to triple production by the end of the decade. Thanks to sizable investments from the big integrated oil majors and oil services companies, it's possible that the country might meet that goal.

Demand in some parts of the world may be waning, but growth elsewhere in the world more than makes up for it. The big market for more oil will be in developing nations, most notably Brazil, China, and India. As long as these countries continue to grow at a staggering pace, they will need oil to fuel that engine. Tune into the video below where Fool.com contributor Tyler Crowe check in with Fool analyst Joel South to discuss the prospects for Middle Eastern oil production and assess the demand from emerging countries.

Top Oil Service Companies To Invest In 2015: CSB Bancorp Inc (CSBB)

CSB Bancorp, Inc. (CSB), incorporated in 1991, is a financial holding company. The Commercial and Savings Bank of Millersburg, Ohio (the Bank) is a wholly owned subsidiary of the Company. CSB operates primarily through the Bank and its other subsidiaries, providing a range of banking, trust, financial and brokerage services to corporate, institutional and individual customers throughout northeast Ohio. The Bank provides retail and commercial banking services to its customers, including checking and savings accounts, time deposits, individual retirement accounts (IRAs), safe deposit facilities, personal loans, commercial loans, real estate mortgage loans, installment loans, night depository facilities, brokerage and trust services.

Lending Activities

The Bank provides residential real estate, commercial real estate, commercial and consumer loans to customers located primarily in Holmes, Tuscarawas, Wayne, Stark and portions of surrounding counties in Ohio. Commercial loan rates are variable as well as fixed, and include operating lines of credit and term loans made to small businesses, primarily based on their ability to repay the loan from the cash flow of the business. Business assets, such as equipment, accounts receivable and inventory typically secure such loans. Commercial real estate loans are primarily secured by borrower-occupied business real estate. Commercial real estate loans are generally originated with a loan-to-value ratio of 80% or less. Commercial construction loans are secured by commercial real estate and in most cases the Bank also provides the permanent financing. Residential real estate loans carry both fixed and variable rates and are secured by the borrower�� residence. Home equity lines of credit are made to individuals and are secured by second or first mortgages on the borrower�� residence. Installment loans to individuals include loans secured by automobiles and other consumer assets, including second mortgages on personal residences.

Investment Activities

As of December 31, 2011, the Company�� securities available-for-sale totaled $123,026,000. Its portfolio of securities available-for-sale includes the United States treasury securities, the United States Government corporations and agencies, mortgage-backed securities, obligations of states and political subdivisions, equity securities, and corporate bonds.

Sources of Funds

As of December 31, 2011, the Company�� portfolio of deposits included noninterest-bearing demand, interest-bearing demand deposits, savings deposits and time deposits. Short-term borrowings consist of securities sold under agreements to repurchase, short-term advances through Federal Home Loan Bank and federal funds purchased.

Advisors' Opinion:

• [By CRWE]

  Today, CSBB remains (0.00%) +0.000 at $18.75 thus far (ref. google finance Delayed: 3:53PM EDT July 30, 2013).

  CSB Bancorp, Inc. previously reported second quarter 2013 net income of $1.25 million or $.45 per basic and diluted share, as compared to $1.14 million or $.41 per basic and diluted share for the same period in 2012.

  Annualized returns on average common equity (��OE�� and average assets (��OA�� for the quarter were 9.32% and 0.88%, respectively, compared with 8.98% and 0.82% for the second quarter of 2012.

  Eddie Steiner, President and CEO commented, ��e continue to focus on growing relationships with current and new customers. The bank�� average loan balances have increased 10% in the past year, and although margins remain tight, this growth has provided increases of approximately 4% in net interest income.��/p>

Top Oil Service Companies To Invest In 2015: AU Optronics Corp (AUO)

AU Optronics Corp. engages in the design, development, manufacture, assembly, and marketing of thin film transistor liquid crystal displays and other flat panel displays. The company operates in two segments, Display and Solar. It offers a range of display panels for use in mobile PCs, such as notebooks and tablets; desktop monitors; consumer electronics products consisting of mobile phones, digital still cameras, portable navigation displays, digital camcorders, automobile displays, amusement and printer displays, and portable gaming consoles; and LCD televisions. The company sells its panels to original equipment manufacturing service providers who manufacture products on a contract basis for brand companies; and to brand companies on a direct shipment basis. It also manufactures upstream and midstream products, such as polysilicons, ingots, wafers, and solar cells; designs, develops, and manufactures solar photovoltaic (PV) modules; produces solar PV systems; and provid es various value-added services for solar PV systems projects. AU Optronics Corp. operates in the People�s Republic of China, Taiwan, Singapore, Korea, and internationally. The company was formerly known as Acer Display Technology, Inc. and changed its name to AU Optronics Corp. in May 2001. AU Optronics Corp. was founded in 1996 and is based in Hsinchu, Taiwan.

Advisors' Opinion:

• [By Seth Jayson]

  Basic guidelines
  In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at AU Optronics (NYSE: AUO  ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is AU Optronics doing by this quick checkup? At first glance, pretty well. Trailing-12-month revenue increased 6.5%, and inventory decreased 13.1%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue increased 14.9%, and inventory contracted 13.1%. Over the sequential quarterly period, the trend looks worrisome. Revenue dropped 7.7%, and inventory grew 7.7%.

• [By Monica Gerson]

  AU Optronics (NYSE: AUO) shares reached a new 52-week low of $3.06. AU Optronics' PEG ratio is 2.34.

  CBL & Associates Properties (NYSE: CBL) shares fell 5.20% to reach a new 52-week low of $18.43 after the company reported Q3 results.

5 Best Wireless Telecom Stocks To Own Right Now: Permian Basin Royalty Trust (PBT)

Permian Basin Royalty Trust (the Trust), incorporated in 1980, is an express trust. The Trust's principal assets are net overriding royalties conveyed to the Trust, including a 75% net overriding royalty carved out of Southland Royalty�� fee mineral interests in the Waddell Ranch in Crane County, Texas (the Waddell Ranch properties), and a 95% net overriding royalty carved out of Southland Royalty�� major producing royalty interests in Texas (the Texas Royalty properties). Bank of America, N.A. is the Trustee for the Trust.

Waddell Ranch Properties

The mineral interests in the Waddell Ranch, from which such net royalty interests are carved, vary from 37.5% (Trust net interest) to 50% (Trust net interest) in 78,715 gross (34,205 net) producing acres. A majority of the proved reserves are attributable to six fields: Dune, Sand Hills (Judkins), Sand Hills (McKnight), Sand Hills (Tubb), University-Waddell (Devonian) and Waddell. At December 31, 2012, the Waddell Ranch properties contained 889 gross (400 net) productive oil wells, 64 gross (30 net) productive gas wells and 177 gross (506 net) injection wells.

Burlington Oil & Gas Company LP (BROG) is the operator of the Waddell Ranch properties. As of December 31, 2012, six major fields on the Waddell Ranch properties account for more than 80% of the total production. In the six fields, there are 12 producing zones ranging in depth from 2,800 to 10,600 feet. Most prolific of these zones are the Grayburg and San Andres, which produce from depths between 2,800 and 3,400 feet. Also productive from the San Andres are the Sand Hills (Judkins) gas field and the Sand Hills (McKnight) oil field, the Dune (Grayburg/San Andres) oil field, and the Waddell (Grayburg/San Andres) oil field.

The Dune and Waddell oil fields are productive from both the Grayburg and San Andres formations. The Sand Hills (Tubb) oil fields produce from the Tubb formation at depths averaging 4,300 feet, and the University Waddell (Devo! nian) oil field is productive from the Devonian formation between 8,400 and 9,200 feet. The Waddell Ranch properties are producing properties, and all of the major oil fields are being waterflooded for the purpose of facilitating enhanced recovery. As of December 31, 2012, there were no drill wells and 13 workovers in progress on the Waddell Ranch properties.

Texas Royalty Properties

The Texas Royalty properties consist of royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others located in 33 counties across Texas. The Texas Royalty properties consist of approximately 125 separate royalty interests containing approximately 303,000 gross (approximately 51,000 net) producing acres.

Advisors' Opinion:

• [By Lawrence Meyers]

  Permian Basin Royalty Trust (PBT) is a royalty trust, meaning it pools together royalty rights for various energy-producing properties. �I prefer trusts that are widely diversified.� In this case, Permian holds a 75% net overriding royalty interest in six properties in Crane County, Texas; and a 95% net overriding royalty interest in fields spread across 33 other counties in Texas.� In total, we��e talking 400 oil wells, 30 gas wells, and 500 injection wells. �That�� plenty diversified.� Yeehaw for its 8.3% yield!

• [By Rick Munarriz]

  Permian Basin Royalty Trust (NYSE: PBT  ) is also flowing more freely with its distributions. The trust's new rate of $0.088488 per unit may seem to be a numerical stretch, but it's a healthy 45% pop from its prior monthly payout. Increased oil production and higher oil prices helped the company generate more money that it passes on to its investors.

Top Oil Service Companies To Invest In 2015: Timeless Software Ltd (TLW)

Timeless Software Limited is an investment holding company mainly engaged in the provision of computer consultancy and software maintenance services, software development and sales of computer hardware and software. It operates in four divisions: software development, hardware sales, software sales and e-commerce services. As of March 31, 2012, the Company�� subsidiaries included Three Principles Computer Service Company Limited, which is engaged in the provision of computer consultancy services, development and sales of computer software; Encore Trading Limited, which is engaged in the trading of computer software and hardware and provision of information technology consultancy services in Hong Kong; Timeless Northern Software (Beijing) Company Limited, which is engaged in design, development and maintenance of computer software and systems, as well as provision of computer consultancy services, and other subsidiaries. Advisors' Opinion:

• [By Namitha Jagadeesh]

  IAG, the parent of British Airways, climbed 3 percent to 373.6 pence and Air France advanced 1.5 percent to 7.62 euros. BG Group Plc (BG/), the third-biggest oil and gas producer listed in the U.K., dropped 1.2 percent to 1,245 pence and Tullow Oil Plc (TLW) retreated 1.4 percent to 875 pence.

Top Oil Service Companies To Invest In 2015: Boston Scientific Corp (BSX)

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women�� Health, Neuromodulation, and Electrophysiology. In January 2011, it completed the acquisition of Intelect Medical, Inc. In January 2011, it completed the acquisition of Sadra Medical, Inc. In March 2011, the Company completed the acquisition of Atritech, Inc. In February 2011, it announced the acquisitions of S.I. Therapies and ReVascular Therapeutics, Inc. In January 2011, the Company sold its Neurovascular business to Stryker Corporation. In June 2012, the Company acquired Cameron Health, Inc. of San Clemente, California and, as a result, added to its product portfolio subcutaneous implantable cardioverter defibrillator, called the S-ICD System.

Interventional Cardiology

The Company offers coronary stent product. Coronary stents are tiny, mesh tubes used in the treatment of coronary artery disease, which are implanted in patients to prop open arteries and facilitate blood flow to and from the heart. The Company offers a two-drug platform strategy with its paclitaxel-eluting and everolimus-eluting stent system offerings, and it offers a range of stent sizes. The Company markets its next-generation internally-developed and self-manufactured PROMUS Element stent system in the United States, its Europe/Middle East/Africa (EMEA) region and certain Inter-Continental countries, including China and India. It markets the PROMUS everolimus-eluting stent system, supplied to the Company by Abbott Laboratories, in Japan. It also markets its TAXUS paclitaxel-eluting stent line, including its third-generation TAXUS Element paclitaxel-eluting stent system in the U.nited States, Japan, EMEA and certain Inter-Continental countries.

The Compa! ny markets a line of products used to treat patients with atherosclerosis, a principal cause of coronary artery obstructive disease. Its product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA). The Company markets a family of intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels. The iLab Ultrasound Imaging System continues as its flagship console and is compatible with its line of imaging catheters. The system is designed to enhance the diagnosis and treatment of blocked vessels and heart disorders. Sadra is developing a repositionable and retrievable device for transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis. The Lotus Valve System consists of a stent-mounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve. Atritech has developed a device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke. The WATCHMAN Left Atrial Appendage Closure Technology, developed by Atritech, is the first device proven in a randomized clinical trial to offer an alternative to anticoagulant drugs, and is approved for use in CE Mark countries.

Cardiac Rhythm Management

The Company develops, manufactures and markets a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including Implantable cardioverter defibrillator (ICD) systems used to detect and treat abnormally fast heart rhythms (tachycardia) that could result in sudden cardiac death, including implantable cardiac resynchronization therapy defibrillator (CRT-D) systems used to treat heart failure, and implantable pacemaker systems used to manage slow or irregular heart rhyth! ms (brady! cardia), including implantable cardiac resynchronization therapy pacemaker (CRT-P) systems used to treat heart failure. Its product offerings include its COGNIS cardiac resynchronization therapy defibrillator (CRT-D), its TELIGEN ICD systems and its ALTRUA family of pacemaker systems. During 2011, it began the United States launch of its next-generation line of defibrillators, INCEPTA, ENERGEN and PUNCTUA.

Endoscopy

The Company markets a range of products to diagnose, treat and ease a variety of digestive diseases, including those affecting the esophagus, stomach, liver, pancreas, duodenum, and colon. Common disease states include esophagitis, portal hypertension, peptic ulcers as well as esophageal, biliary, pancreatic and colonic cancer. The Company offers the Radial Jaw 4 Single-Use Biopsy Forceps, which are designed to enable collection of large high-quality tissue specimens without the need to use large channel therapeutic endoscopes. Its exclusive line of RX Biliary System devices are designed to provide greater access and control for physicians to diagnose and treat challenging conditions of the bile ducts, such as removing gallstones, opening obstructed bile ducts and obtaining biopsies in suspected tumors. The Company also markets the Spyglass Direct Visualization System for direct imaging of the pancreatico-biliary system. The Spyglass System is a single-operator cholangioscopy device that offers clinicians a direct visualization of the pancreatico-biliary system and includes supporting devices for tissue acquisition, stone management and lithotripsy. Its products also include the WallFlex family of stents, in particular, the WallFlex Biliary line and WallFlex Esophageal line; and in 2011, the Company launched its Advanix Biliary Plastic Stent System and the Expect Endoscopic Ultrasound Aspiration Needle in the United States and certain international markets. Its Resolution Clip Device is an endoscopic mechanical clip designed to treat gastrointestinal bleeding.

T! he Company markets devices to diagnose, treat and ease pulmonary disease systems within the airway and lungs. Its products are designed to help perform biopsies, retrieve foreign bodies from the airway, open narrowings of an airway, stop internal bleeding, and ease symptoms of some types of airway cancers. Its product line includes pulmonary biopsy forceps, transbronchial aspiration needles, cytology brushes and tracheobronchial stents used to dilate narrowed airway passages or for tumor management. Asthmatx, Inc. designs, manufactures and markets a less-invasive, catheter-based bronchial thermoplasty procedure for the treatment of severe persistent asthma. The Alair Bronchial Thermoplasty System, developed by Asthmatx, has both CE Mark and Food and Drug Administration (FDA) approval and is the first device-based asthma treatment approved by the FDA.

Peripheral Interventions

The Company sells various products designed to treat patients with peripheral disease, including a line of medical devices used in percutaneous transluminal angioplasty and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. In 2010 and 2011, it launched several of its products internationally, including the EPIC self-expanding nitinol stent system in certain international markets, and the Carotid WALLSTENT stent system in Japan. The Company launched three new peripheral angioplasty balloons in 2011, including its next-generation Mustang percutaneous transluminal angioplasty (PTA) balloon, its Coyote balloon catheter, a highly deliverable and ultra-low profile balloon dilatation catheter designed for a range of peripheral angioplasty procedures and its Charger PTA Balloon Catheter, a 0.035 inch percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation, as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company has commenced a limited ma! rket rele! ase of its OFFROAD re-entry catheter system in certain international markets, and in February 2012, it launched its TRUEPATH intraluminal CTO device in the United States.

The Company sells products designed to treat patients with non-vascular disease. Its non-vascular suite of products include biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continues to market its extensive line of Interventional Oncology product solutions, including the Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. The Company�� FilterWire EZ Embolic Protection System is a filter designed to capture embolic material that may become dislodged during a procedure, which could otherwise travel into the microvasculature where it could cause a heart attack or stroke. It is commercially available in the United States, its EMEA region and certain Inter-Continental countries for multiple indications, including the treatment of disease in peripheral, coronary and carotid vessels. It is also available in the United States for the treatment of saphenous vein grafts and carotid artery stenting procedures.

Urology/Women�� Health

The Company�� Urology/Women�� Health division develops, manufactures and sells devices to treat various urological and gynecological disorders. The Company sells a variety of products designed to treat patients with urinary stone disease, stress urinary incontinence, pelvic organ prolapse and excessive uterine bleeding. The Company offers a line of stone management products, including ureteral stents, wires, lithotripsy devices, stone retrieval devices, sheaths, balloons and catheters.

The Company markets a range of devices for the treatment of conditions, such as female urinary incontinence, pelvic floor reconstruction (rebuilding of the anatomy to its original state), and ! menorrhag! ia (excessive menstrual bleeding). It offers a breadth of mid-urethral sling products, sling materials, graft materials, pelvic floor reconstruction kits, and suturing devices. The Company markets its Genesys Hydro ThermAblator (HTA) system, a next-generation endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. The Genesys HTA System features a smaller and lighter console, simplified set-up requirements, and an enhanced graphic user interface and is designed to improve operating performance.

Neuromodulation

The Company within its Neuromodulation business markets the Precision Spinal Cord Stimulation (SCS) system, used for the management of chronic pain. In 2011, the Company launched its Clik Anchor for its Precision Plus SCS System, a rechargeable SCS device for chronic pain management. During 2011, it received FDA approval for and launched the Infinion 16 Percutaneous Lead, a 16-contact percutaneous lead. The Company also markets the Linear 3-4 and Linear 3-6 Percutaneous Leads for use with its SCS systems, which are designed to provide physicians more treatment options for their chronic pain patients. Intelect Medical, Inc. is a development-stage company developing advanced visualization and programming for the Vercise system.

Electrophysiology

The Company within its Electrophysiology business develops less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart. Included in its product offerings are radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Its products include the Blazer and Blazer Prime line of temperature ablation catheters, designed to deliver enhanced performance, responsiveness, and durability. Its cooled ablation portfolio includes the closed-loop irrigated catheter on the market, the Chilli II cooled! ablation! catheter, and the newly launched Blazer Open-Irrigated ablation catheter with a Total Tip Cooling Design.

The Company competes with Abbott Laboratories, Medtronic, Inc., St. Jude Medical, Inc. and Johnson & Johnson.

Advisors' Opinion:

• [By Johanna Bennett]

  With its stock price already doubled in value over the last 12 months, is it time to back away from shares of Boston Scientific (BSX)? Cowen & Co. analyst Joshua Jennings doesn�� think so.

• [By Nikolaj Gammeltoft]

  Boston Scientific Corp. (BSX) soared 13 percent to $10.96. The second-biggest maker of heart-rhythm devices reported profit that beat analysts��estimates and raised its forecast amid signs that demand for defibrillators and stents is starting to stabilize.

• [By Sean Williams]

  Shares of medical-device maker Boston Scientific (NYSE: BSX  ) jumped 3.6% after the company announced on Friday that it had launched a clinical trial to evaluate if occipital nerve stimulation using its Precision System can safely treat chronic migraine when used with existing anti-migraine medications. Migraines are still a largely misunderstood disease, and the current medication available could definitely get better, leaving the door wide open for Boston Scientific should this trial prove fruitful. With Boston Scientific shares cresting $10 for the first time in three years shareholders are certainly pumped, but I'd reserve that optimism until its bottom line profits catch-up with its now loftier valuation.